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Abstract: The authors in the current work suggested the potential repurposing of omarigliptin (OMR)
for neurodegenerative diseases based on three new findings that support the preliminary finding
of crossing BBB after a single dose study in the literature. The first finding is the positive results of
the docking study with the crystal structures of A2A adenosine (A2AAR) and acetylcholine esterase
(AChE) receptors. A2AAR is a member of non-dopaminergic GPCR superfamily receptor proteins
and has essential role in regulation of glutamate and dopamine release in Parkinson’s disease while
AChE plays a major role in Alzheimer’s disease as the primary enzyme responsible for the hydrolytic
metabolism of the neurotransmitter acetylcholine into choline and acetate. Docking showed that
OMR perfectly fits into A2AAR binding pocket forming a distinctive hydrogen bond with Threonine
256. Besides other non-polar interactions inside the pocket suggesting the future of the marketed
anti-diabetic drug (that cross BBB) as a potential antiparkinsonian agent while OMR showed perfect
fit inside AChE receptor binding site smoothly because of its optimum length and the two fluorine
atoms that enables quite lean fitting. Moreover, a computational comparative study of OMR docking,
other 12 DPP-4 inhibitors and 11 SGLT-2 inhibitors was carried out. Secondly, glucagon-like peptide-1
(GLP-1) concentration in rats’ brain tissue was determined by the authors using sandwich GLP-1
ELISA kit bio-analysis to ensure the effect of OMR after the multiple doses’ study. Brain GLP-1
concentration was elevated by 1.9-fold following oral multiple doses of OMR (5 mg/kg/day, p.o.
for 28 days) as compared to the control group. The third finding is the enhanced BBB crossing of
OMR after 28 days of multiple doses that had been studied using LC-MS/MS method with enhanced
liquid–liquid extraction. A modified LC-MS/MS method was established for bioassay of OMR in
rats’ plasma (10–3100 ng/mL) and rats’ brain tissue (15–2900 ng/mL) using liquid–liquid extraction.
Alogliptin (ALP) was chosen as an internal standard (IS) due to its LogP value of 1.1, which is very
close to the LogP of OMR. Extraction of OMR from samples of both rats’ plasma and rats’ brain
tissue was effectively achieved with ethyl acetate as the extracting solvent after adding 1N sodium
carbonate to enhance the drug migration, while choosing acetonitrile to be the diluent solvent for
the IS to effectively decrease any emulsion between the layers in the stated method of extraction.
Validation results were all pleasing including good stability studies with bias of value below 20%.
Concentration of OMR in rats’ plasma were determined after 2 h of the latest dose from 28 days
multiple doses, p.o, 5 mg/kg/day. It was found to be 1295.66 ± 684.63 ng/mL estimated from
the bio-analysis regression equation. OMR passed through the BBB following oral administration
and exhibited concentration of 543.56 ± 344.15 ng/g in brain tissue, taking in consideration the
dilution factor of 10. The brain/plasma concentration ratio of 0.42 (543.56/1295.66) was used to
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illustrate the penetration power through the BBB after the multiple doses for 28 days. Results showed
that OMR passed through the BBB more effectively in the multiple dose study as compared to the
previously published single dose study by the authors. Thus, the present study suggests potential
repositioning of OMR as antiparkinsonian agent that will be of interest for researchers interested in
neurodegenerative diseases.
Keywords: repurposing; omarigliptin; docking; A2A adenosine receptor; acetylcholine esterase
receptor; GLP-1; rats’ plasma; rats’ brain tissue; 28 days multiple doses; LC-MS/MS

1. Introduction
Drug repurposing is a novel research topic as a substitute to underperforming hypothesisdriven molecular target-based drug discovery efforts [1]. De novo drug discovery is an
outdated perspective that is pricey process. Thus, drug repurposing was a substitute
strategy as therapeutic conversion of a drug that is already marketed is less time consuming [2]. It has proven to be a preferred approach for enhanced drug discovery that carries
less risk due to the presence of previous pharmacological, safety, and toxicology data [3]
with many positive studies in the literature [4,5]. Omarigliptin (OMR) is a novel once
weekly anti-diabetic drug [6]. Dipeptidyl peptidase-4 (DPP-4) inhibitors are well-known
effective potential agents against type 2 diabetes mellitus (DM). OMR is a long-acting once
weekly administered DPP-4 inhibitor (Figure 1a), that prolongs the half-life of glucagonlike peptide-1 (GLP-1) and increases the insulin production [7–17] as a treatment against
type 2 DM. The once-weekly OMR has the advantage of more patient compliance than the
other daily-administered DPP-4 inhibitors. Unlike the classical once-daily DPP-4 inhibitors,
once-weekly administration could boost the patients’ compliance [18]. Interestingly, this
will depict a major outcome if the drug had been repositioned successfully for Parkinson’s
disease (PD) or at least as a neuroprotective agent against other neurodegenerative diseases. PD is the most prevalent movement neuro-degenerative disease [19] and this study
aims to develop new curative agents for PD achieving wide safety margin implementing
repositioning. Repositioning of a once-weekly anti-diabetic drug for the management of
PD will promote the patient’s adherence with potential financial privilege due to onceweekly dosing regimen. Indeed, the potential neuroprotective effect of GLP-1 had been
previously reported owing to the promising antiparkinsonian effect of DPP-4 inhibitors
(Gliptins, anti-diabetics) [20,21]. Many gliptins exhibited neuro-restorative effects in previous PD studies related to DPP-4 inhibition as sitagliptin, saxagliptin, linagliptin, and
vildagliptin [22–28]. Additionally, a new study recommended repositioning of teneligliptin
to brain conditions [29]. Drug repositioning represents the most novel approach in drug
development due to its efficiency and lower economic burden. Drug repurposing is an
uprising revolution of drug discovery that presents major and prominent privilege with
already approved safer agents by scanning the current candidates.
Although a literature review shows that OMR pharmacokinetics factors and/or bioanalysis were studied in human [7–14] and rats [15–17] successfully according to the
common FDA bioanalytical guidelines [30]. All articles considered only the plasma parameters through bio-analysis either human plasma or rats’ plasma. While only one article that
was published by (Ayoub et al.) considered the bioanalysis of OMR in rats’ brain tissue [17].
However, that method [17] used only direct precipitation as an extraction technique for
OMR using acetonitrile. Extraction was enhanced after using ethyl acetate as the extracting
solvent accompanied with adding 1N sodium carbonate to enhance the drug migration.
In addition, extraction was enhanced after decreasing any emulsion between the layers
in the liquid–liquid extraction effectively using acetonitrile as the diluent solvent for the
IS [31]. It is worth mentioning that the described extraction method was a slightly modified
method applicable on both rats’ brain tissue and rats’ plasma samples and it had been
firstly described and used for human plasma samples by Addy and Tatosian et al. [10–13].
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As per FDA guidelines, the bio-analytical method validation was established to include
4 of 24
linearity, precision, selectivity, accuracy, carry over, extraction recovery, stability studies,
and matrix factor [30]. Alogliptin (ALP) was used as an internal standard (IS) due to its
LogP value of 1.1, which is very close to the LogP of OMR. Extraction of OMR from both
rats’ plasma and rats’ brain tissue samples was successfully achieved.
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Figure 1. (a) Chemical structure of OMR, (b) chemical structure of IS, (c) daughter of OMR, and (d)
daughter of IS.

Figure 1. (a) Chemical structure of OMR, (b) chemical structure of IS, (c) daughter of OMR, and (d)
daughter of IS.
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In the previously published article by (Ayoub et al.), it showed the preliminary OMR
successful BBB crossing [17], direct precipitation followed by LC-MS methods were performed for determination of OMR and trelagliptin in rats’ plasma and brain tissue (after
single dose of 5 mg/kg of OMR and 20 mg/kg of trelagliptin) to show their interaction
with BBB to check for the opportunity of their repositioning as neuroprotective agents.
Trelagliptin showed negative results while OMR crossed BBB successfully after the single
dose. The proposed advanced current repositioning study of OMR in the underlying article
is based on the docking study, the enhanced GLP-1 concentration in brain after the multiple
dose study and finally the brain/plasma concentration ratio after multiple doses (28 days).
Pharmaceutical industry and researchers working in PD treatment will highly benefit from
this study. As per FDA guidelines [30], a complete validation of the new LC-MS/MS
methods (that based on liquid–liquid extraction and vacuum evaporation for rats’ plasma
and brain tissue) was developed. The validated methods will be suitable to researchers
and QC laboratories for further pharmacokinetic and clinical studies. The new methods
can also be used for further future studies (CDRD-BUE) calculating AUCbrain /AUCplasma
after single and/or multiple dose pharmacokinetics (I.V., oral, intranasal, nanoformula
to increase BBB crossing, etc.) in case of positive anti-parkinsonian results with different
dose/response studies. Liquid–liquid extraction was common in the literature for extraction of many drugs from both animal plasma and brain extract [32–34] with high sensitivity
(to overcome the limitation of high LLOQ in the pilot study with direct precipitation [17]).
Working on the concentration ratio (brain/plasma) after multiple dose administration to
rats (28 days), will offer interesting data about the behavior of OMR crossing the BBB on
the long-term treatment plan.
2. Methods
2.1. Docking Study of OMR, Other 12 DPP-4 Inhibitors and 11 SGLT-2 Inhibitors with A2A
Adenosine Receptor (A2AAR) and Acetylcholinesterase (AChE) Receptor
OMR was docked into the crystal structures of A2AAR and AChE receptors. Moreover,
for a computational comparative study of OMR docking involving 12 DPP-4 inhibitors
and 11 SGLT-2 inhibitors was carried out. The 3D receptors’ structures were downloaded
from Protein Data Bank (Codes: 3PWH and 6F25, respectively), then their preparation was
implemented using MakeReceptor app of OpenEye Scientific Software tools. Different
gliptins (DPP-4 inhibitors) and gliflozins (SGLT-2 inhibitors) were studied separately, and
their energy were minimized using Open Babel software applying MMFF94 molecular
force field. The docking calculations were proceeding on the protein model by FRED
docking app of OpenEye.
2.2. Chemicals and Reagents
Various batches of blank rats’ plasma and rats’ brain tissue homogenate (10%) were
prepared directly before the experimental work in the Center for Drug Research and
Development at the British University in Egypt (CDRD-BUE). All the plasma and brain
tissue samples were withdrawn as fresh samples in the animal house unit (CDRD) after
the approval of the ethical committee (BUE). OMR raw material (99.0%), the raw material
of alogliptin, which was used as IS, was certified to contain (99.2%) ethyl acetate were a
generous gift thankfully provided by (CDRD, BUE). Acetonitrile, water, and methanol
of HPLC grade and formic acid were acquired from (Sigma, USA). Sandwich ELISA kit
(CUSABIO, CSB-E08117r) was used for GLP-1 estimation in rats’ brain tissue samples.
The surfactant was used as 2.5% (w/v) aqueous solutions: Tween-80 was purchased from
(El-Nasr Pharmaceutical Chemicals Co., Cairo, Egypt) in addition to sodium carbonate.
2.3. Biological Samples after Ethical Approval, Determination of Brain GLP-1 Concentration, and
Multiple Dose In Vivo BBB Crossing Test
All experimental protocols and underlying methods were approved by the ethical
committee of faculty of Pharmacy The British University in Egypt. Twenty rats (250 g ± 35)
were randomly assigned into two groups (n=10); the first group was administered OMR
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(5 mg/kg/day, p.o.) for 28 days while the second group served as control. Rats’ dose was
calculated in accordance with the FDA guidelines for human-rodent dose conversions [35].
GLP-1 brain concentration was assessed in both experimental groups. Also, LC-MS/MS
was used for quantitative determination of OMR in plasma and brain tissue after oral
administration to rats (n=10). The design of the study is a multiple dose study for 28 days
based on 5 mg/kg/day, p.o. It is worth noting that tween 80 surfactant (2.5%, w/v) was
essential to solubilize the hydrophobic OMR in saline (p.o). After 2 h of the latest dose
after 28 days of OMR drug administration, 0.8 mL blood samples were collected into
heparinized tubes via rats’ tail vein (except the control group). The separated plasma
(>300 µL) was pipetted to clean tubes and stored at −80 ◦ C until analysis. All twenty rats
were then sacrificed and the whole brain of each animal was separated, washed in saline,
homogenized (10%, w/v in saline) using Ultra-Turrax® homogenizer and kept frozen at
−80◦ C until LC-MS/MS analysis and GLP-1 ELISA kit analysis. The brain homogenate
was centrifuged at 3000 rpm for 3 min then the supernatant was used for determination of
GLP-1 concentration using Sandwich ELISA kit (CUSABIO, CSB-E08117r) according to a
reported method [36]. Statistical analysis was performed using GraphPad Prism (version 7,
ISI® software, USA). GLP-1 results were expressed as the mean ± SEM and analyzed
using two-tailed Student’s t-test test. Probability values lower than 0.05 were considered
statistically significant. Also, the current study aimed to investigate whether the crossing
ability of OMR for the BBB will be enhanced after the multiple dose for 28 days and to
assess if the developed LC-MS/MS method is valid for the bioassay of OMR in the actual
biological samples (plasma and brain tissue). The dilution factor of 10 was taken into
consideration for all brain tissue calculations (LC-MS/MS and ELISA).
2.4. LC-MS/MS Conditions
The following conditions were implemented based on the previously published work
by Ayoub et al. after minor modifications to increase the sensitivity (published preliminary
repositioning study on OMR using direct precipitation as an extraction technique for rats’
plasma [17] by Ayoub et al.). LC-MS/MS was performed via Waters® UPLC-TQ with ESI,
Mass Lynx software (4.2 version) and ACQUITY UPLC® BEH shield RP C18 column (1.7 µm,
150 × 2.1 mm), (WATERS, Ireland, serial 01853004518304). Mobile phase of acetonitrile/0.3
formic acid (90:10, v/v) in the isocratic mode, 10 µL as the injection volume, 0.3 mL/min
as the flow rate and 1.5 min as the run time for OMR bio-assay, were adopted. The mass
spectrometer parameters included the adjustment of cone voltage values to 40 V and 30 V
and collision energy values to 50 eV and 55 eV for OMR and alogliptin (IS), respectively.
MRM of m/z equals 399.2 to 153.0 for OMR and m/z equals 340.2 to 116.0 for alogliptin
IS in the ESI positive mode was applied (Figure 1). MS tuning was implemented and the
stated parameters were adopted: turbo ion spray at 400 ◦ C, capillary temperature at 275 ◦ C,
sheath gas at 15 psi, auxiliary gas at 2 psi, ion spray voltage at 5500 V, capillary voltage at
4 kV, capillary offset at 35, desolvating line temperature at 400 ◦ C, source temperature at
130 ◦ C, and desolvation gas flow at 600 L/h.
2.5. LC-MS/MS Calibrators, QC Samples, and Sample Preparation
OMR standard stock solution in methanol was prepared as (1 mg/mL) then working
solutions were prepared using methanol as a solvent with multiple concentrations (1, 3, 5,
25, 40, 85, 150, 200, and 310 µg/mL). Ten microliters of each one of the prepared working
solutions was used to spike 990 µL blank plasma to prepare calibrators as 10 ng/mL
(LLOQ), 50, 250, 850, 1500, and 3100 ng/mL. QC samples were selected to be 30, 400,
2000 ng/mL as LQC, MQC, and HQC, respectively. While for brain homogenate samples
(10%); working solutions with different concentrations were prepared in methanol (1.5, 3,
6, 15, 40, 60, 130, 200, and 290 µg/mL). A 10-microliter measure of each one of the prepared
working solutions was used to spike 990 µL brain homogenate sample 10% to prepare
calibrators as 15 ng/mL (LLOQ), 60, 150, 600, 1300, and 2900 ng/mL. QC samples were
selected to be 30, 400, 2000 ng/mL as LQC, MQC, and HQC, respectively. For samples
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preparation, an aliquot of 300 µL of each plasma sample (or brain homogenate sample 10%)
was spiked with 100 µL of the IS in acetonitrile (300 ng/mL), then 100 µL of 1 N sodium
carbonate was added, followed by liquid–liquid extraction by 1.5 mL of ethyl acetate
for 15 min centrifugation at 15,000 rpm. 1.3 mL of the upper organic level was vacuum
evaporated until dryness followed by reconstituted with 300 µL methanol and then injected
into the auto-sampler. Peak area ratios to IS was used against concentrations to estimate the
calibration curve and the regression equation. The final brain samples’ concentrations were
calculated as ng/g brain tissue after considering the dilution factor of 10.
2.6. LC-MS/MS Bioanalytical Validation
According to FDA guidelines [30] six calibrators were performed to estimate the
linearity while LLOQ, LQC, MQC, HQC levels (n = 5) were determined to predict accuracy
and precision five times a day and on three consecutive days. The final brain samples’
concentrations were calculated as ng/g brain tissue after considering the dilution factor
of 10. The bias value, standard deviation (S.D.) and % RSD were estimated. Selectivity
was determined by checking interference in six different batches of blank rats’ plasma and
rats’ brain tissue homogenate (10%) that had been prepared at (CDRD-BUE) as mentioned
under Section 2.2. Injection of blank samples directly after the high values of concentration
was performed to confirm the lack of a carryover of a notable value. The matrix effect was
estimated by comparing the area ratios under the peak of the post extracted samples to
the neat standards. While the extraction recovery was estimated by comparing the area
ratios under the peak of the underlying pre-extracted samples (spiked before extraction)
to the post-extracted samples (spiked after extraction). The dilution integrity experiment
for the rats’ plasma method was carried out at 5 times and 10 times dilution of the high
concentration 3500 ng/mL and their concentrations were calculated, while for the brain
homogenate experiment, it was carried out at 5 times and 10 times dilution of the high
concentration 3000 ng/mL. Both high concentrations for the two experiments were higher
than the upper limit of quantification. The percentage change from the comparison sample
should be within ±15%. Stability of LOQ and HQC was determined based on four different
bioassays including, leaving the samples in the auto-sampler for 3 h, leaving them at room
temperature for 3 h (bench top short-term stability), analyzing them after three complete
cycles of freeze and thaw, and finally, freezing the samples at −80 ◦ C for two weeks was
performed to inspect the long-term stability.
3. Results and Discussion
3.1. Comparative Docking Study (OMR, DPP-4 Inhibitors, and SGLT-2 Inhibitors) with A2AAR
and AChE Receptors
3.1.1. Comparative Docking Study of DPP-4 Inhibitors with A2AAR that Support
Repurposing of OMR for Parkinson’s’ Disease
Virtual simulation could be a guide in understanding activity or even anticipating
certain pharmacological activity or analytical finding. Such a multifactorial disease like
Parkinson’s, is affected by modulation of several proteins offering different treatment
pathways and agents. It is considered that increasing the human body’s ability to control
the blood sugar will result in better central and neurological functions. In addition, some
recent DPP-4 inhibitors’ studies approved the achieving of central neuroprotective effects.
In general, mediating certain activity via different mechanisms that has been coined polypharmacology would result in improved total efficacy. A docking simulation approach
would enable identification of drugs into not kindred protein targets. Where is the study
aiming to find out whether OMR after passing BBB would achieve central anti Parkinson
activity or not, OMR was docked into the crystal structures of the A2A adenosine receptor
(A2AAR) that is a member of non-dopaminergic GPCR superfamily receptor proteins and
has essential role in regulation of glutamate and dopamine release. The crystal structure of
the receptor that strongly enriched known ligands and has a comparably open binding site
conformation was chosen (PDB code 3PWH). The co-crystallized ligand chemically named
[4-{2-[(7-amino-2-furan-2-yl[1,2,4]triazolo[1,5-a][1,3,5]triazin-5 yl)amino]ethyl}phenol] was
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used to identify the active binding sites. Molecular docking calculations were achieved using OpenEye tools. At first, preparation of protein by MakeReceptor, energy minimization
of OMR, generating all possible conformers and then docking via FRED. Docking shows
that OMR is perfectly fit into binding pocket forming a distinctive hydrogen bond with
Threonine 256, besides other non-polar interactions inside pocket, this shown in Figure 2
while Figure S1 in Supplementary Materials shows reliable score of the docking simulation with co-crystallized ligand. The difference in binding energy between the docked
conformer of OMR and co-crystalized ligand in protein 3D structure was studied (as in
Molecules 2021, 26, x FOR PEER REVIEW
8 ofthe
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Figure S1 in the Supplementary Materials) and the lower the energy of the conformer,
more predicted stability of the drug-receptor complex.
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OMEGA was possible [45]. The docking calculations were proceeding on the protein model
by FRED docking app of OpenEye. All the 13 gliptins were fitted well in receptor pocket
identified using the co-crystalized ligand. Two gliptins namely Alogliptin (Figure S2 in
Supplementary Materials) and Linagliptin (Figure S3 in Supplementary Materials) scored
a lower energy that suggest better affinity while fitting than the ligand after predicting
the binding mode with 3PWH of each drug. Unfortunately, this better affinity does not
ensure a better activity because of the lack of BBB crossing data about both alogliptin and
linagliptin which is the main strength point for OMR. Furthermore, alogliptin made two
hydrogen bonds with Asparagine 253 in binding site. In addition, teneligliptin, evogliptin,
and anagliptin were found to hydrogen bond with asparagine 253, glutamic acid 169,
and alanine 63, respectively. All of them showed perfect alignment inside the identified
binding site. Figures S2 and S3 (in Supplementary Materials) confirmed the validation
of docked structures inside the binding pocket achieving the anticipated effect. These
figures do emphasize that if those gliptins crossed BBB, they do have the ability to fit in
the desired receptor pocket achieving reasonable stable low energy complex. Docking
scores are summarized in Table 1. Table 1 shows the docking energy result obtained from
OpenEye. This score is of absolute value and it is directly related to the drug-receptor
complex energy. The lower energy, the more stable the complex yet they all fit within the
binding pocket. Other parameters may interfere like physical properties of each hit. In
spite of OMR, not getting the highest score, to the latest of the authors knowledge, it is the
only reported gliptin that crossed BBB—suggesting its higher exposure to the receptor in
the brain.
Table 1. Docking energy scores of 13 gliptins and 11 gliflozins with A2AAD and AChE receptors.

AChE Receptors

SGLT2
Inhibitors

Score

DPP4 Inhibitors

Score

Ipragliflozin

−18.0826

Linagliptin

−16.7927

Luseogliflozin

−17.4729

Sitagliptin

−14.6245

Canagliflozin

−16.6481

Gemigliptin

−14.3007

Dapagliflozin

−16.4979

Anagliptin

−14.2372

Empagliflozin

−15.7074

Gosogliptin

−13.9488

Sotagliflozin

−15.5315

Teneligliptin

−13.7557

Tofogliflozin

−15.1791

Saxagliptin

−13.2396

Ertugliflozin

−14.4763

Omarigliptin

−13.1468

Sergliflozin

−13.4309

Alogliptin

−13.1226

Remogliflozin

−12.2717

Evogliptin

−13.0186

Ligand

−9.8658

Vildagliptin

−12.727

Dutogliptin

−12.1961

Ligand

−11.0175

Trelagliptin

N/A
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Table 1. Cont.

A2A AR
Receptors

SGLT2
Inhibitors

Score

DPP4 Inhibitors

Score

Canagliflozin

−13.5012

Linagliptin

−11.6503

Empagliflozin

−13.0962

Alogliptine

−11.14

Ertugliflozin

−12.9675

Ligand

−10.7851

Luseogliflozin

−12.2521

Trelagliptin

−10.778

Ipragliflozin

−12.1433

Sitagliptin

−10.3922

Dapagliflozin

−12.0988

Tenegliptin

−10.2282

Sotagliflozin

−11.9531

Gosogliptin

−9.8775

Tofogliflozin

−11.2769

Evogliptin

−9.8116

Sergliflozin

−11.2085

Geminigliptin

−9.7432

Ligand

−10.7851

Anagliptin

−9.2179

Remogliflozin

−8.7495

Vildagliptin

−9.0521

Dutogliptin

−8.5373

Omarigliptin

−8.4469

Saxagliptin

−8.3109

3.1.2. Off-Label Neuroprotective Effect of DPP-4 Inhibitors and SGLT-2 Inhibitors and How
the Brain Is Insulin Dependent
A complicated chronic disease like type-2 diabetes mellitus (DM) is distinguished by
its continuous need of monitoring to avoid harmful consequences. Main complications of
DM includes dysfunction in ocular, nervous, cardiovascular, and renal systems. It results
from insufficient insulin secretion or impaired tissue sensitivity to insulin or both [46]. Most
recently, our research group studied two main classes of oral antidiabetic agents; namely,
DPP-4 inhibitors which collectively known as gliptins and the other class are sodium
glucose cotransporter-2 (SGLT2) inhibitors which also collectively known as gliflozins.
Both are acting by indirect route affecting sugar level in blood. DPP-4 inhibitors lessen the
breakdown of GLP-1, which is the major responsive glucose incretin hormone. The role of
the unhydrolyzed GLP-1 intact hormones is to influence insulin secretion with the increase
in blood glucose level. DPP-4 inhibitors are having lower potential to cause hypoglycemia
as the resultant GLP-1 is secreted in case of high blood glucose level only [47,48]. SGLT2
inhibitors are located chiefly in the early proximal tubule in kidneys responsible for 80–90%
of glucose reabsorption. By blocking their action most of reabsorbed glucose is then
secreted in urine. This led to immediate lose in blood glucose without affecting any other
signal mechanism [49].
The central effect of insulin has recently been proven in literature. This demonstrates
why controlling blood glucose levels is in direct relation with better brain activities and
cognitive functions [50]. In other words, the brain is an insulin responsive organ, studies
include deletion of brain insulin receptors in mice results in hyperphagia, obesity, and
dysfunction in insulin metabolic homeostasis [51]. Another recent study presented brain
insulin resistance led to certain behavioral disorders and anxiety [52]. Generally, improper
insulin signaling in the brain has a direct role in pathogenesis of insulin resistance occurs
in DM, cognitive defects, and memory problems [53,54]. The case of impaired peripheral
insulin production and sensitivity in DM not only results in complications and symptoms
related to endocrine malfunctions, but also brain dysfunctions indicated by brain mitochondrial dysfunction, increased brain oxidative stress, impaired brain insulin receptor
function, impaired synaptic plasticity, and overall cognitive decline [55–57].
This was validated by studies that shows direct or indirect changes in brain activity
and functions when administering oral antidiabetics agents especially the most recently
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DDP-4 inhibitors. This class shows glycemia-independent advantageous outcomes in
different studies adapting animal models of Parkinson’s disease and Alzheimer’s disease.
However, there is no officially approved repositioned agent administered for a brain
disorder. Yet ongoing and recent studies discuss the ability of other oral hypoglycemic
agents for doing central therapeutic effects. Upon literature review of the recent antidiabetic
agent that may play a double role in both DM and some cognitive disease, gliflozins appears
to have a high potential [17,23,25,26].
SGLT2 receptors are also found in human brain doing the function of giving away
glucose. A study of regional distribution of SGLT in rat brain, showed its presence in
forebrain (in the caudate nucleus putamen and frontal cortex) and Midbrain (in the hippocampus, hypothalamus, parietal cortex, amygdala, and thalamus) [58]. Some studies of
different animal models support this proposed role of SGLT2 inhibitors in elevating and
promoting cognitive effects. A very recent model of Alzheimer’s disease on mixed murine
rats, showed the impact of one of gliflozins; empagliflozin in decreasing vascular defect
and cognitive deterioration. Long-term treatment with empagliflozin largely preserve
memory and learning abilities of diabetic rats. Moreover, some cognitive improvement is
resulted by a reduction of oxidative stress markers, better insulin signaling, and increased
synaptic activity in the hippocampus [59]. Empagliflozin role seems to be related the attenuation of oxidative stress and reduction of cerebral superoxide and 8-OHdG. Attenuation
of cerebral oxidative stress is mainly connected to a reduction in cerebral NADPH oxidase
subunits, gp91phox and p67phox levels. Moreover, empagliflozin directly affect cerebral
BDNF [60], a key protein promoting memory and survival of neurons, that is significantly
decreased in DM patients and its decline is associated with cognitive decline. Interestingly, empagliflozin treatment significantly increased cerebral BDNF levels [61]. Other
cognitive changes in diabetic mice after empagliflozin treatment, includes improvement
in mice performance in object discrimination tests, along with increased neurogenesis in
the dentate gyrus and synaptophysin in the striatum oriens [62]. Another study assessed
the neuroprotective activity of the SGLT2 inhibitor dapagliflozin in combination with
the GLP-1 agonist liraglutide in dietary-induced diabetic mice. In all treatment groups,
recognition memory was significantly improved brain histology demonstrated increased
staining (number of immature neurons) in dentate gyrus and synaptophysin (synaptic
density) in stratum oriens and stratum pyramidale [62]. In which SGLT protein receptors
are highly normally expressed [58].
The main problem with testing gliflozins and gliptins in brain is the insufficient
data for their ability of passing blood brain barrier. There are assumptions of presence
of these antidiabetic agents centrally in brain and other opinions suppose not and its
SGLT2 inhibition modulates the autonomic nervous system in the kidneys. Signals from
the kidney may be transmitted to the brain via the autonomic nervous system, thereby
changing specific setpoints. This is an attempt to correlate molecular findings to put
more light on the role of insulin as a whole-body affecting agent. Furthermore, this helps
clinically in providing the optimum management of DM and its cognitive complications by
providing a better understanding of oral hypoglycemic behavior and the role of insulin in
brain functions. Therefore, the following computational study was carried out to calculate
the binding energy between all gliflozins and gliptins with isolated crystal structure of
some brain receptors of cognitive disorders like AChE enzyme receptor, for Alzheimer’s
disease and A2AAR that plays a role in Parkinson’s disease. This might provide data for
knowing the central mechanism of action of DPP-4 and SGLT2.
More than 30 years ago, GLP-1 was proposed to be a possible target to cure DM [63], as
its infusion lessen total body need to insulin. It was already known that insulin response for
oral sugar ingestion is greater than that is of intravenous infusion [64]. This was termed “the
incretin effect” and attributed to stimulation of insulin secretion by incretins [65]. All DPP-4
inhibitors have the same anti-diabetic effects. The monotherapy results in smaller HbA1c
reductions than metformin, but in sum, they are clinically equivalent to sulfonylureas
and thiazolidinediones, when they are in combination with metformin [66]. Moreover,
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combination with metformin was related directly to lower gastric adverse effects [66,67].
Both metformin and DPP-4 inhibitors are the best initial combination in case of elevated
HbA1c levels and could be also used in with lower values of HbA1c. This was introduced
lately by the abbreviation VERIFY (vildagliptin efficacy in combination with metformin for
early treatment of type 2 diabetes) study [68,69].
On the other hand, SGLT2 inhibitors was initially developed over the occurrence
of phlorizin, which is a natural glycoside of plant origin. Phlorizin, the phytochemical
obtained from apple tree bark was found to inhibit SGLT activity. After that when the
mechanism of glucose transport was determined, optimum understanding of SGLTs and
their main functional characteristics was gained [70–72]. Meanwhile SGLT2 inhibitors
manifested clinical supremacy regarding hyperglycemia, visceral adiposity, and body
weight. In addition, they ameliorate other metabolic problems come in line with high blood
pressure, risky lipid profile, or uric acid level [73]. Cardiovascular outcome trials (CVOTs)
of SGLT2 inhibitors showed better outcomes in diabetic or even nondiabetic patients [74,75].
SGLT transporters are one of SLC5 gene family [76]. Genes in this family include sugartransporting proteins, anions (SLCSAS and SLC5A8), vitamins (SLC5A6), choline (SLC5A7),
and one glucose sensor (SLC5A4) [77,78]. The main glucose transporters are SGLT1 and
SGLT2. However, both do the same function, but they differ widely in properties [79,80].
Normally, blood glucose is accumulated to the side of glomerular membrane through
tubular lumen. About 150 g of glucose is being filtered each day. However, per usual,
these glucoses readily reabsorbed [81–83]. Glucose reabsorption is done over two steps,
firstly at the basolateral membrane of proximal convoluted tubule. Where both SGLT1 and
SGLT2 actively transport glucose in an ATPase facilitated diffusion into tubular epithelium
cells. Second stage is mainly derived via glucose itself, that passively pass to plasma
via Glucose transporter 2 [GLUT2] [84]. It is worth mentioning that, generally, glucose
reabsorption in DMT2 patients is higher than normal and that is because of SGLT1 and
GLUT2 overexpression [85,86].
As a new aminopeptidase with novel unique characteristics, DPP-4 was discovered
in 1966 [87]. In 1992, its gene was identified on the long arm of (2q24.3 chromosome 2)
encoding protein of 766-amino acids [88–90]. It is a member of gene family knowns as
serine peptidase/prolyl oligopeptidase, which is subclassified by function or structure [91].
This DPP-4 protein is vastly expressed in several body tissues from endothelial cells in many
vascular beds [92], rendering its circulatory substrates found within kidney, liver, lung, and
gut [93]. DPP-4 act by transmitting signals across cell membrane plus interconnecting with
other proteins in membrane. Curiously, the largest part of protein located extracellular and
just six amino acids are merged into cell cytoplasm [37,94]. Meanwhile, a soluble form of
DPP-4 is produced and liberated into plasma leading to its activity in human serum [95,96].
This active soluble form was found initially in saliva and serum then it had been detected in
cerebrospinal fluid and bile [97]. More research is needed for understanding the mechanism
by which DPP-4 starts a signal transduction cascade. It may occur through reaction with
mannose 6-phosphate/IGF-2 receptor [98] or through other molecular interactions [99].
It is becoming obvious: brain is an insulin sensitive organ that controls many metabolic
signal cascades [100]. Constant ATP supply in brain needs constant glucose uptake, which
it turns controls general brain energetics. That is why the need for insulin emerges as a
preventing factor for neurodegenerative disorders [101–105]. Insulin can enter the brain
directly via blood–brain barrier (BBB) or indirectly via cerebrospinal fluid as a surrogate, in
which insulin low concentrations transported through the endothelium locally in a region
namely Virchow–Robin space [106]. Insufficient insulin led to impaired glucose uptake.
Overtime, that would ruin ion transportation and recycling within vesicles heading to improper synaptic signaling within brain [107–109]. Inefficient perpetuation of ion gradients
disrupts release of brain transmitters and a consecutive of adverse events would occurs
including hyperexcitability, excitatory–inhibitory imbalance. These would all diminish the
brain energy functions. These mentioned alterations result in worsening glutamatergic
transmission and oligodendrocyte function and absolutely lead to total nutrient recycling
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reduction [110–112]. In fact, hypo-metabolism of glucose in brain has no obvious single
cause. It may be out of reduction glucose uptake, a problem in aerobic glycolysis and in
tricarboxylic acid cycle. Other factors may contribute, like inefficient axonal transport or
decrease in glial energy support of the neurons [113,114].
3.1.3. Docking Study of OMR (and 12 Other DPP-4 Inhibitors) with AChE Receptor
A computational comparison study of OMR and the other DPP-4 inhibitors (Table 1)
was carried out after docking with AChE, which plays the main role in Alzheimer’s disease.
This is come in line with studies utilized the same protein with the same Protein Data
Bank code for testing new synthesized hits acting against Alzheimer’s diseases [49]. The
3D receptor structure was downloaded from Protein Data Bank (Code 6F25). Protein was
initially prepared, using MakeReceptor app of OpenEye Scientific Software tools [50–52].
Thirteen DPP-4 inhibitors were studied and energy minimized using Open Babel software
applying MMFF94 molecular force field [53]. Subsequently generation of all possible
conformers of all via OMEGA [54]. The docking calculations were proceeding on the protein
model by FRED docking app of OpenEye. DPP-4 inhibitors with AChE receptor adapt
different binding behaviors due to lack of structure similarity between the gliptins as shown
in (Figure S4 in the Supplementary Materials). However, they fit inside receptor binding
site smoothly because of their optimum length. Some of them made HB interactions,
sitagliptin—the second best docked—with PHE 295 also Anagliptin made two HBs with
SER 203 and TYR 124. It is worth noting that (AChE) crystal structure shows one hydrogen
bond with SER 125 in addition to the other non-bonding interactions. The remarkable
finding is that the longer the designed structure the better to fit in the C shaped receptor
pocket (Figure S5 in the Supplementary Materials).
OMR achieved a binding score lower than the ligand when docked with AChE
(Figure 3). Yet, over observation of its proposed behavior with pocket, no polar interaction
was found. The sulfonyl moiety with its two lone pairs is slightly protruded in the pocket
center with no interactions with the surrounded amino acids. On the other point, deep
inside binding site the benzene moiety with two fluorine atoms made a quite lean fitting.
No hindrance was noticed between the conformer and adjoining residues in binding site.
It is worth noting that trelagliptin failed in achieving acceptable docking result with
AChE as shown as N/A score in Table 1. Although the structural similarity between
trelagliptin and alogliptin with only one fluorine atom as the difference between the two
structures, alogliptin showed a perfect fit while trelagliptin did not which is attributed to
the extra fluorine atom. The fluorine atom in trelagliptin hindered its fitting inside the
pocket. Meanwhile, Alogliptin is fitted well forming two hydrogen bonds with TYR 124 and
SER 203, plus the fitting within narrow bridge in receptor (Figure S6 in the Supplementary
Materials). Although adding such a fluorine atom enhanced its anti-diabetic activity, on
the other side, it seems that it decreases its neuroprotection.
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initiating the bonding mechanism then each structure according to its length continue to fit
in the C-shaped pocket structure of the receptor. The remarkable finding that the docking
scores of gliflozins and gliptins are much higher than those of the co-crystalized ligand
implementing the same molecular dynamics and docking algorism.
3.2. GLP-1 Concentration
The brain glucagon-like peptide-1 (GLP-1) concentration was elevated by 1.9-fold following oral multiple doses of OMR (5 mg/kg/day, p.o. for 28 days) as compared to the control group (Figure 4). Concentration of GLP-1 is the drug group was 50.72 pg/mL ± 2.04
(SEM) while it was found to be 26.87 pg/mL ± 0.649 (SEM) in the control group which
means more insulin sensitivity in the brain. It is becoming obvious: brain is an insulin
sensitive organ that controls many metabolic signal cascades. Constant ATP supply in
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The brain glucagon-like peptide-1 (GLP-1) concentration was elevated by 1.9-fold
following oral multiple doses of OMR (5 mg/kg/day, p.o. for 28 days) as compared to the
control group (Figure 4). Concentration of GLP-1 is the drug group was 50.72 pg/mL ±
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2.04 (SEM) while it was found to be 26.87 pg/mL ± 0.649 (SEM) in the control group which
means more insulin sensitivity in the brain. It is becoming obvious: brain is an insulin
sensitive organ that controls many metabolic signal cascades. Constant ATP supply in
brain needs constant glucose uptake, which it turns controls general brain energetics. That
brain needs constant glucose uptake, which it turns controls general brain energetics. That
is why the need for insulin with high sensitivity in the brain emerges as a preventing
is why the need for insulin with high sensitivity in the brain emerges as a preventing
factor for neurodegenerative disorders and that was achieved by OMR. In addition, confactor for neurodegenerative disorders and that was achieved by OMR. In addition, controlling blood glucose levels by OMR is in direct relation with better brain activities and
trolling blood glucose levels by OMR is in direct relation with better brain activities and
cognitive functions.
cognitive functions.
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m/z equals 340.2 to 116.0 for ALP was used in positive electro spray ionization (ESI) mode
(Figure 1). Only one article that was published (by Ayoub et al.) considered the bioanalysis
of OMR in rats’ brain tissue [17]. However, that method [17] used only direct precipitation
with acetonitrile as an extraction technique for OMR. The lower limit of quantification
(LLOQ) was 50 ng/mL [17], which is considered very high compared to the LLOQ in
the present work (15 ng/mL). It is worth noting that the reported method [17] was not
applicable in the current investigation that detected mean OMR brain tissue concentration
of 543.56 ng/mL after considering the dilution factor of 10. The measured concentration
before the dilution factor was 54.3 ng/mL, which is almost, equal to or very close to the
LLOQ value of 50 ng/mL by Ayoub et al. method [17]. While that problem was solved by
the described enhanced liquid–liquid extraction that showed LLOQ of 15 ng/mL which
is suitable and applicable for the measured concentration after 28 days of multiple doses.
Not only the extraction with ethyl acetate lowered the LLOQ but also using acetonitrile as
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the solvent for the IS decreased the emulsion between the matrix and the extracting solvent
layers as the major advantages for the described method rather than the reported one [17].
It is worthy to mention that the reported bioanalytical method [17] that was published
(by Ayoub et al.) included only single dose study of OMR after only 1 h of administration
to rats while the current work included 28 days multiple doses study that simulate the
long-term use of the drug in human consumption. Moreover, the current work included
determination of GLP-1 concentration in brain tissue after 28 days multiple doses of OMR
that showed a significant difference which is compatible with the findings of enhanced
BBB crossing activity after the multiple doses. Furthermore, a part of the underlying work
covered the comparative docking study, which was not included by any means in reference
17. Usually, studying multiple doses is preferred to a single dose to show the cumulative
effects of the drug after metabolism and long-term exposure.
It is worth noting that the described extraction method was a slightly modified
method applicable on both rats’ brain tissue and rats’ plasma samples and it had been
firstly described and used for human plasma samples by Addy and Tatosian et al. [10–13].
Extraction of OMR from both rats’ plasma and rats’ brain tissue samples was successfully
achieved with ethyl acetate as the extracting solvent after adding 1N sodium carbonate
to enhance the drug migration, while choosing acetonitrile as the diluent solvent for the
IS effectively decrease the emulsion between the layers in the liquid–liquid extraction
followed by vacuum evaporation till dryness and reconstitution. Improved extraction
was effectively attained after using acetonitrile as the diluent solvent for the IS decreasing
the emulsion formed due to the addition of the aqueous immiscible organic solvent ethyl
acetate [31]. Therefore, using an adequate mixture of the extracting solvent with high
volume of acetonitrile; leads to decreasing the formed emulsion, and therefore allow the
precise withdrawing of up to 1.3 mL from the upper pure organic layer.
Working on finding a suitable extraction method for both plasma and brain samples
was a challenge in the current investigation. Although literature review showed the use
of direct precipitation technique [16,17], the preliminary investigations in the described
current research—using liquid–liquid extraction technique—showed clear enhanced results. In the previously published article [14], a mixture of diethyl ether and tertiary butyl
methyl ether was used for the optimum extraction of OMR from human plasma. We tried
the extraction of OMR from rats’ plasma using the same mixture [14] and it was successful
because of that the rats’ plasma samples are less complicated matrix in comparison to
human plasma samples but that was not the case in case of brain tissue samples. The main
aim of the work was investigating OMR ratio (brain/plasma) applying the same extraction
procedure to eliminate the error sources in calculations and partition coefficient. Moreover,
many organic solvents had been tried before by Ayoub et al. in a previously published
article [15] dealing with liquid–liquid extraction of OMR that included dichloromethane,
hexane, ethyl acetate while all those extracting solvents showed less extracting power
than ether without alkalinization. It is worthy to mention that when applying the method
described in many articles (dealing with human plasma) based on ethyl acetate and alkalization with sodium carbonate [10–13], it showed the best results for both plasma and
brain tissue. In spite of ethyl acetate is partially soluble in water, and therefore, it will
extract all the nonpolar compounds and some polar metabolites, and the supernatant will
contain a considerable portion of water, making it more tedious to evaporate it; in the
current investigation, it showed the best recoveries especially for brain tissue samples
after alkalinization.
Validation results were all satisfactory. Calibration (10–3100 ng/mL for rats’ plasma
and 15–2900 ng/mL for brain homogenate), and full validation results were acceptable
with FDA bio-analytical guidelines [30]. Appropriate method selectivity from six different batches of blank rats’ plasma and blank brain homogenate was designated where no
notable interference was detected among the MRM channels in blank, zero samples with
IS and reasonable outcomes at the LLOQ level (Figure 5A,B) and no notable carry over
was observed as carry over percent was found to be 9.6% after plasma samples while it
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was found to be 8.1% after brain homogenate samples. The equations of the rats’ plasma
and brain homogenates’ calibration curves were (y = 0.0103x + 0.0349, r = 0.9995) and
(y = 0.0073 + 0.0309, r = 0.9997), respectively. Accuracy (n=5) and precision (n=15) were
within ± 20% as shown in (Table 2). For the rats’ plasma method, extraction recovery
was 74.62% for the LOQ and 80.13% for the HQC sample while they found to be (69.27%)
and (72.53%), respectively for the brain homogenate method. Matrix factor signifying the
effect of the matrix on the signal response and the ionization efficiency through matrix
enhancement and/or suppression was calculated. It was found to be from 87.78% to
93.4% showing ion suppression for all concentrations of OMR in plasma while it ranged
from 73.67% to 82.76% regarding the brain homogenate indicating more ion suppression.
Dilution integrity results for rats’ plasma were acceptable after dilution of 3500 ng/mL
5 times (R% = 100.92 ± 6.48) and 10 times (R% = 93.48 ± 4.84) were acceptable. Dilution
integrity results for rats’ brain homogenate were acceptable after dilution of 3000 ng/mL
5 times (R% = 90.32 ± 1.54) and 10 times (R% = 111.49 ± 12.87) were acceptable. Stability measurements stated under ‘methods’ indicated recoveries more than 80% (Table 3)
that indicates OMR stability can be sustained through the sample treatment and storage.
Working with high percent acetonitrile at the isocratic mode ensured the outcome of a very
fast bio-analytical method suitable for the bio-analysis of more than 100 samples per day
with enough selectivity, accuracy, and precision according to ICH guidelines. The authors
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used LC-MS/MS technique mainly as a ‘detection’ rather than ‘separation’ technique.
Moreover, studying selectivity confirmed the absence of any interfering peaks from the
studied different batches of blank matrix either for the rats’ plasma or rats’ brain tissue.
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4. Conclusions
As OMR crosses BBB successfully, its docking study results was more interesting
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Table 2. Accuracy and precision results for OMR determination by the proposed LC-MS/MS.
Accuracy and Precision

Parameters

LLOQ

LQC

MQC

HQC

Rats’ plasma intra-day

Mean of R%
Bias
S.D.
C.V. (%RSD)

118.72
18.72
13.03
10.97

99.47
−0.53
10.95
11.01

91.43
−8.57
7.21
7.89

103.42
3.42
8.76
8.47

Rats’ plasma inter-day

Mean of R%
Bias
S.D.
C.V. (%RSD)

99.81
−0.19
17.78
17.81

101.75
1.75
9.60
9.43

91.09
−8.91
6.68
7.33

101.35
1.35
8.24
8.13

Rats’ brain intra-day

Mean of R%
Bias
S.D.
C.V. (%RSD)

86.99
−13.01
13.29
15.28

87.96
−12.04
10.25
9.62

110.25
10.25
5.67
5.14

109.62
9.62
5.79
5.29

Rats’ brain inter-day

Mean of R%
Bias
S.D.
C.V. (%RSD)

83.23
−16.77
14.04
16.88

90.61
−9.39
8.18
9.03

99.80
−0.20
9.26
9.28

107.24
7.24
5.59
5.21

Where S.D. is the standard deviation, C.V. is the coefficient of variation and %RSD is the percent relative standard
deviation.

Table 3. Stability studies’ results for OMR determination by the proposed LC-MS/MS
Stability Studies

Parameters

Rats’ plasma

Auto-sampler
stability
Short-term stability
Long-term stability
Freeze–thaw stability

Rats’ brain

Auto-sampler
stability
Short-term stability
Long-term stability
Freeze–thaw stability

Recoveries of LQC

Recoveries of HQC

100.58 ± 0.41

100.58 ± 0.41

97.66 ± 1.66
91.43 ± 6.06
107.06 ± 4.99

109.83 ± 6.95
105.17 ± 3.66
111.14 ± 7.88

101.57 ± 1.11

104.97 ± 3.51

96.60 ± 2.40
97.98 ± 1.42
119.73 ± 13.95

106.40 ± 4.53
112.86 ± 9.09
119.57 ± 13.84

On day 28, OMR concentration in rats’ plasma was determined 2 h following the
last dose (Figure 5C). It was found to be 1295.66 ± 684.63 ng/mL calculated from the bioanalysis regression equation. OMR passed through the BBB after the oral administration
(Figure 5D) showing concentration of 543.56 ± 344.15 ng/g in brain tissue after considering
the dilution factor of 10. The brain/plasma concentration ratio of 0.42 (543.56/1295.66) was
used to predict the penetration power through the BBB after the multiple doses for 28 days.
Results indicated that OMR passed through the BBB more effectively in the multiple dose
study as compared to the previously published single dose study by the authors. Thus, the
present study suggests potential repositioning of OMR as an antiparkinsonian agent.
4. Conclusions
As OMR crosses BBB successfully, its docking study results was more interesting than
all the other docking studies for DPP-4 inhibitors and SGLT-2 inhibitors. Docking showed
that OMR is perfectly fit into A2AAR binding pocket forming a distinctive hydrogen bond
with threonine 256, besides other non-polar interactions inside the pocket suggesting the
future of the marketed anti-diabetic drug (that cross BBB) as a potential anti-parkinsonian
agent while OMR showed perfect fit inside AChE receptor binding site smoothly because
of its optimum length that suggests also possible future repurposing as a neuroprotective
agent against Alzheimer disease with the two fluorine atoms that enables quite lean fitting.
Moreover, oral multiple doses of OMR (p.o, 5 mg/kg/day for 28 days) showed 1.9 times
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increase in brain GLP-1 concentration in comparison to the control group which means
more insulin sensitivity in the brain. It is becoming obvious: brain is an insulin sensitive
organ that controls many metabolic signal cascades. Constant ATP supply in brain needs
constant glucose uptake, which it turns controls general brain energetics. That is why
the need for insulin with high sensitivity in the brain emerges as a preventing factor for
neurodegenerative disorders and that was achieved by OMR. In addition, controlling
blood glucose levels by OMR is in direct relation with better brain activities and cognitive
functions. Finally, as per FDA guidelines, bio-analysis of OMR using LC-MS/MS was
established. Liquid–liquid extraction and reconstitution after vacuum evaporation was
applied. The LLOQ in the present investigation is less than three times of the previous
LLOQ stated by (Ayoub et al.). Enhancing the extraction techniques for new drugs enrich
the literature and opens the door for more pharmacokinetic and bioequivalence studies.
The brain/plasma concentration ratio of 0.42 (543.56/1295.66) was used to estimate the
penetration power through the BBB after the multiple doses for 28 days. Results indicated
that OMR crossed the BBB more effectively in the multiple dose study than the single dose
study suggesting its possible repositioning as antiparkinsonian agent that will be of great
impact for researchers concerned with neurodegenerative diseases.
Supplementary Materials: The following are available online. Figure S1: Docking score of OMR
(Fragment No#2) relative to the receptor ligand, Figure S2: Predicted binding mode of alogliptin with
3PWH of A2AAR, Figure S3: Predicted binding mode of linagliptin with 3PWH of A2AAR, Figure
S4: DPP-4 inhibitors with AChE receptor adapt different binding behaviors due to lack of structure
similarity between the gliptins, Figure S5: The remarkable finding that the longer the designed
structure the better to fit in the C shaped receptor pocket, Figure S6: Alogliptin is fitted well with
AChE forming two hydrogen bonds with TYR 124 and SER 203, plus the fitting within narrow bridge
in receptor, Figure S7: Different binding behavior of SGLT2 inhibitors and the cocrystlized ligand (in
pink) of 6f25 in PDB.
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